Immuneering
IMRX
49 hedge funds and large institutions have $176M invested in Immuneering in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 19 increasing their positions, 6 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
217% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 6
53% more capital invested
Capital invested by funds: $115M → $176M (+$61M)
44% more funds holding
Funds holding: 34 → 49 (+15)
14.32% more ownership
Funds ownership: 44.72% → 59.04% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.5M |
| 2 |
BlackRock
New York
|
+$10.4M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$5.94M |
| 4 |
Goldman Sachs
New York
|
+$4.45M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$959K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$563K |
| 3 |
Jane Street
New York
|
-$452K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$318K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$288K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$563K | -57,949 | Closed |
|
|
52
Jane Street
New York
| – | -$452K | -46,571 | Closed |
|
|
YIH
53
Y-Intercept (HK)
Hong Kong
| – | -$108K | -11,114 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$26.3K | -2,713 | Closed |
|
IMRX Hedge Fund Activity: Q2 2023 in Review
49 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q2 2023, worth a combined $176M — up 53% from $115M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IMRX positions and 5 closed out — a net gain of 15 holders — while 19 added to existing stakes and 6 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $17.5M. The largest seller was Millennium Management, exiting entirely with an estimated $959K sold.
- 49 institutional investors held Immuneering (IMRX) as of Q2 2023, up from 34 in Q1 2023.
- Funds reported $176M of Immuneering stock for Q2 2023, up 53% quarter-over-quarter.
- 20 funds opened new Immuneering positions in Q2 2023 and 5 closed out, a net change of +15 holders.
- The largest Immuneering buyer in Q2 2023 was Cormorant Asset Management, an estimated $17.5M added.
- The largest Immuneering seller in Q2 2023 was Millennium Management, an estimated $959K sold.
Based on aggregated 13F filings for Q2 2023.